Proactive Investors - Run By Investors For Investors

Alliance Pharma receives Irish green light for nausea drug

Xonvea will be prescribed to women who are sick during pregnancy where conservative treatment has failed
pregnant woman
The drug will go on sale in Ireland towards the end of the year

Alliance Pharma PLC (LON:APH) has confirmed its morning sickness treatment Xonvea has received marketing approval in Ireland.

This paves the way for the first launch of the product outside the UK. The company to start selling the drug in the Republic in the final quarter of this year.

As in the UK, it will be prescribed for nausea and vomiting in pregnancy where conservative management has failed.

The condition affects 70-80% of women during pregnancy in Ireland, mirroring what is seen in Britain.

View full APH profile View Profile

Alliance Pharma PLC Timeline

January 21 2019

Related Articles

February 01 2019
The cancer detection device is on track to finish a key clinical study in the first quarter of 2019, but in the meantime, it has shown promise in detecting abnormalities in unborn children
September 17 2018
The company is utilising technology and big data to tackle the growing healthcare crisis and personalise treatment options for preventative care.
February 20 2019
Earlier this month, Tissue Regenix reported full-year results showing revenues more than doubled last year to £11.6mln, up from £5.2mln a year earlier
Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use